What is the typical cerebrospinal fluid (CSF) picture in a patient with suspected anti-N-methyl-D-aspartate (NMDA) receptor encephalitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CSF Picture in Anti-NMDAR Encephalitis

The CSF in anti-NMDAR encephalitis is frequently abnormal, particularly in the first phase of illness, showing lymphocytic pleocytosis (up to 500 cells/μL) with detectable NMDA receptor antibodies. 1

Key CSF Findings

Cell Count

  • Lymphocytic pleocytosis is present in approximately 58-60% of patients, with white cell counts that can reach up to 500 cells/μL 1, 2
  • The CSF pleocytosis is especially prominent during the first phase of illness when patients present with seizures, confusion, amnesia, and psychosis 1
  • Cell count elevation is more frequent in anti-NMDAR encephalitis compared to other antibody-mediated encephalitides 3

Protein

  • Protein elevation is relatively uncommon, occurring in only 18.6% of cases 2
  • CSF protein content does not significantly differ from controls and is not a reliable diagnostic marker 3

Oligoclonal Bands (OCB)

  • OCB are present in approximately 34-40% of anti-NMDAR encephalitis patients 3
  • The presence of OCB is significantly more frequent in anti-NMDAR encephalitis compared to non-autoimmune controls, with 8.5-fold higher likelihood 3
  • OCB have high specificity (96%) but low sensitivity (34%) for the diagnosis 3

Antibody Detection

  • NMDA receptor antibodies are detectable in CSF and are more sensitive than serum testing 1, 4
  • 100% of patients with positive serum antibodies have positive CSF samples, while only 62.8% of CSF-positive patients have positive serum 2
  • CSF antibody testing is not essential for diagnosis as antibodies are also present in serum, but paired samples are most informative 1

Other Parameters

  • CSF pressure is increased in approximately 39.5% of patients 2
  • Blood-CSF barrier dysfunction (QAlb>Qlim) occurs in 29.3% of cases 2
  • Intrathecal immunoglobulin synthesis is detected in only 17.1% of patients 2

Clinical Correlation

The typical patient is a 25-year-old female (male:female ratio 1:2) who often presents with headache and fever as early symptoms, mimicking a prodromal viral infection 1. The illness progresses through two distinct phases:

  • First phase: Seizures, confusion, amnesia, and psychosis with more prominent CSF abnormalities 1
  • Second phase: Involuntary movements (choreoathetosis, orofacial dyskinesia), fluctuating consciousness, dysautonomia, and central hypoventilation 1

Important Caveats

  • CSF abnormalities do not correlate with prognosis or outcome 2
  • A normal CSF does not exclude anti-NMDAR encephalitis—approximately 40-42% of patients have normal CSF cell counts 1, 2
  • Anti-NMDAR antibodies can be detected in approximately 30% of patients during herpes simplex encephalitis, so positive results must be interpreted in clinical context 5
  • The median hospital stay is 160 days (range 16-850 days), with many patients requiring ICU admission for assisted ventilation 1

Diagnostic Approach

Both serum and CSF should be tested for NMDA receptor antibodies when possible, as CSF testing has higher sensitivity 5, 2, 4. However, immunotherapy should be initiated as soon as infection is excluded based on basic CSF results (cell count, protein, glucose), without waiting for antibody confirmation 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Anti-NMDA Receptor Autoimmune Encephalitis: Diagnosis and Management Strategies.

International journal of general medicine, 2023

Guideline

NMDA Receptor Antibody Testing in Epilepsy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of NMDA Receptor Encephalitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the clinical significance of a negative cerebrospinal fluid (CSF) N-methyl-D-aspartate (NMDA) receptor antibody test in a patient with suspected autoimmune encephalitis?
What is NMDA (N-methyl-D-aspartate) receptor-associated encephalitis?
What is NMDAR (N-methyl-D-aspartate) encephalitis?
What are the cerebrospinal fluid (CSF) findings in systemic lupus erythematosus (SLE) patients with limbic encephalitis?
What is ataxia in an older adult patient presenting with symptoms similar to Parkinson's disease, such as grip loss and motor symptoms?
What is the likely diagnosis for an elderly man with intermittent right anterior shoulder pain and soreness when lying on the affected side, following band exercises to strengthen the rhomboids and improve posture?
What is the diagnosis for a patient with a 4-month history of diarrhea, passing mucus, and anemia, who has a family history of colon cancer, with a relative who had abdominal pain relieved by defecation at 60 years old, and has a normal Erythrocyte Sedimentation Rate (ESR)?
What is the best opioid for pain management in a patient with end-stage renal disease (Impaired renal function) due to cancer?
What is the preferred benzodiazepine, Clonazepam (Klonopin) or Lorazepam (Ativan), for treating anxiety disorders in a typical adult patient, considering factors such as seizure history and potential for dependence?
Can Impella (percutaneous left ventricular assist device) be used in patients with end-stage renal disease (ESRD) on continuous renal replacement therapy (CRRT) who develop cardiogenic shock, even in the absence of true cardiogenic causes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.